Harvard Clinical and Translational Science Center

哈佛临床和转化科学中心

• 批准号: 10622007
• 负责人: Lee Marshall Nadler
• 金额: $ 1090.42万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2030-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10622007
• 关键词: Acceleration; Address; Adopted; Boston; COVID-19 pandemic; Center for Translational Science Activities; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials Network; Clinical effectiveness; Collaborations; Communities; Community Health; Competence; Democracy; EHR research; Ecosystem; Education; Effectiveness; Electronic Health Record; Elements; Equity; Evaluation; Faculty; Geography; Goals; Health; Health Sciences; Healthcare; Human; Informatics; Infrastructure; Institution; Institutional Review Boards; Intervention; Laboratories; Leadership; Learning; Logic; Measures; Medical; Medicine; Mentors; Methodology; Methods; Modeling; Multi-Institutional Clinical Trial; Ohio; Oregon; Output; Population Heterogeneity; Process Assessment; Public Health Informatics; Public Health Schools; Research; Research Design; Research Personnel; Resources; Safety; Science; Secure; Special Population; Training; Translational Research; Vision; Work; catalyst; clinical implementation; clinical translation; cohort; digital; education resources; equity, diversity, and inclusion; experience; first-in-human; health inequalities; improved; innovation; insight; interoperability; medical schools; meetings; open data; open source; patient population; pre-clinical; prototype; research and development; sharing platform; success; tool; translational barrier

PROJECT SUMMARY/ ABSTRACT Clinical and translational research (CTR) across Harvard is conducted at 17 independent and geographically dispersed institutions, including Harvard Medical School (HMS), Harvard T. H. Chan School of Public Health, and 15 HMS-affiliated academic health care centers. Each of these institutions is fiscally and operationally independent with their own governance, faculty, IRB, and electronic health records. Harvard Catalyst (HC) serves as the sole coordinating entity for CTR and has brought these institutions together as a federated CTR network. Since 2008, HC has developed a substantial portfolio of educational and CTR resources to meet the needs of the CTR workforce at Harvard and, when their value has been demonstrated at Harvard, disseminated them to the CTSA consortium. Moving forward, HC’s overarching vision is to partner with our CTR workforce, institutions, and communities to become a living clinical and translational science (CTS) learning laboratory. The CTS learning laboratory will continuously assess and reassess the hub’s CTR strengths and weaknesses, developing and implementing programmatic innovations to improve the efficiency, quality, effectiveness, and impact of CTR. Using the principles and methodologies of CTS and guided by a logic model, HC is committed to achieving these goals and overcoming translational roadblocks. Seven translational roadblocks have been prioritized that can be mitigated or overcome: 1) educational resources are not reaching all learners and have been focused on investigators, rather than investigational teams; 2) extensive research resources are frequently invisible and difficult to access; 3) substantial structural and regulatory barriers limit cross-institutional collaborations; 4) research and clinical data need to be connected and their access democratized; 5) CTR workforce is not sufficiently diverse and must be grown in all domains; 6) there is limited access to and participation by diverse populations in research; and 7) insufficient mechanisms exist to support implementation of CTR evidence into practice. HC will also focus on better understanding and meeting the needs of early-stage and underrepresented in medicine investigators and their teams, as well as diverse patient populations and communities, while working to diversify the workforce and reduce health inequities. Multiple initiatives are proposed to address five specific aims: 1) train and diversify the CTR workforce; 2) connect trainees and CTR teams with HC resources; 3) partner with community stakeholders to improve research participation; 4) democratize health informatics; and 5) use CTS to overcome significant CTR roadblocks. HC is eager to learn from other CTSA hubs and is committed to dissemination and sharing across the CTSA consortium. The insights derived from employing CTS approaches will be used to overcome translational roadblocks and advance the collective national goal of improving human health.

项目摘要/摘要 哈佛各地的临床和翻译研究（CTR）在17独立和地理上进行 分散的机构，包括哈佛医学院（HMS），哈佛T. H. Chan公共卫生学院， 和15个HMS相关的学术保健中心。这些机构在财政和操作上都是 独立于自己的治理，教师，IRB和电子健康记录。哈佛催化剂（HC） 是CTR的唯一协调实体，并将这些机构作为联合CTR聚集在一起 网络。自2008年以来，HC开发了大量的教育和CTR资源组合，以满足 哈佛大学的CTR劳动力需求，当他们的价值在哈佛大学展示时 将它们传播到CTSA财团。前进，HC的总体愿景是与我们的合作 CTR劳动力，机构和社区成为活生生的临床和转化科学（CTS） 学习实验室。 CTS学习实验室将继续评估和重新评估枢纽的CTR 优点和劣势，发展和实施程序化创新以提高效率， CTR的质量，有效性和影响。使用CT的原理和方法，并在 逻辑模型HC致力于实现这些目标并克服翻译的障碍。七 已经将转化障碍的优先级列为可以缓解或克服的优先级：1）教育资源是 没有吸引所有学习者，而是专注于调查人员，而不是研究团队； 2） 广泛的研究资源通常是看不见的，难以访问； 3）实质性结构和 监管障碍限制跨机构合作； 4）需要连接研究和临床数据 他们的通道民主化； 5）CTR劳动力还不够多样化，必须在所有领域中生长； 6）潜水员人群参与研究的机会有限； 7）不足 存在支持CTR证据实施实践的机制。 HC也将专注于更好 了解和满足早期的需求，在医学调查人员及其中的人数不足 团队以及多元化的患者人群和社区，同时致力于多样化劳动力和 减少健康不平等。提出了多个计划来解决五个具体目标：1）训练和多样化 CTR劳动力； 2）将培训和CTR团队与HC资源联系起来； 3）与社区合作 利益相关者改善研究参与； 4）民主化健康信息； 5）使用CTS克服 重要的CTR障碍。 HC渴望向其他CTSA枢纽学习，并致力于传播和 在CTSA联盟中共享。采用CTS方法得出的见解将用于 克服翻译的障碍，并促进改善人类健康的集体国家目标。